Current and future prospects for hemophilia gene therapy

References

• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357–2365.
   PubMed Web of Science ®Google Scholar
• Walsh CE, Batt KM. Hemophilia clinical gene therapy: brief review. Transl Res. 2013;161:307–312.
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–2323.
   PubMed Web of Science ®Google Scholar
• Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124:3880–3886.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Martinowitz U, Lissitchkov T, et al. Long acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127:1761–1769.
   Web of Science ®Google Scholar
• Negrier C, Young G, Abdul Karim F, et al. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia. 2016. [Epub ahead of print].
   Google Scholar
• Chuah MK, Evens H, VandenDriessche T. Gene therapy for hemophilia. J Thromb Haemost. 2013;11(Suppl 1):99–110.
   PubMed Web of Science ®Google Scholar
• Ward P, Walsh CE. Targeted integration of a rAAV vector into the AAVS1 region. Virology. 2012;433:356–366.
   PubMed Web of Science ®Google Scholar
• Mimuro J, Mizukami H, Shima M, et al. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals. J Med Virol. 2014;86:1990–1997.
   PubMed Web of Science ®Google Scholar
• Russell DW. AAV vectors, insertional mutagenesis, and cancer. Mol Ther. 2007;15:1740–1743.
   PubMed Web of Science ®Google Scholar
• McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther. 2008;16:1648–1656.
   PubMed Web of Science ®Google Scholar
• McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8:1248–1254.
   PubMed Web of Science ®Google Scholar
• Ferrari FK, Samulski T, Shenk T, et al. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 1996;70:3227–3234.
   PubMed Web of Science ®Google Scholar
• Li C, Narkbunnam N, Samulski RJ, et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther. 2012;19:288–294.
   PubMed Web of Science ®Google Scholar
• Grieger JC, Samulski RJ. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol. 2012;507:229–254.
   PubMed Web of Science ®Google Scholar
• Michelfelder S, Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet. 2009;67:29–60.
   PubMed Web of Science ®Google Scholar
• Van Vliet KM, Blouin V, Brument N, et al. The role of the adeno-associated virus capsid in gene transfer. Methods Mol Biol. 2008;437:51–91.
   PubMedGoogle Scholar
• Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342–347.
   PubMed Web of Science ®Google Scholar
• Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24:257–261.
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther. 2011;11:321–330.
   PubMed Web of Science ®Google Scholar
• Bianconi E, Piovesan A, Facchin F, et al. An estimation of the number of cells in the human body. Ann Hum Biol. 2013;40:463–471.
   PubMed Web of Science ®Google Scholar
• Monahan PE, Sun J, Gui T, et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther. 2015;26:69–81.
   PubMed Web of Science ®Google Scholar
• Tsai SQ, Joung JK. What’s changed with genome editing? Cell Stem Cell. 2014;15:3–4.
   PubMed Web of Science ®Google Scholar
• Faust SM, Bell P, Cutler BJ, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest. 2013;123:2994–3001.
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994–2004.
   PubMed Web of Science ®Google Scholar
• Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361:1671–1675.
   PubMed Web of Science ®Google Scholar
• Chang J, Jin J, Lollar P, et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem. 1998;273:12089–12094.
   PubMed Web of Science ®Google Scholar
• Hoyer LW. Hemophilia A. N Engl J Med. 1994;330:38–47.
   PubMed Web of Science ®Google Scholar
• Lee CA, Berntorp EE, Hoots WK, eds. Textbook of hemophilia. Malden, MA: Blackwell; 2005.
   Google Scholar
• Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia. 2014;20(Suppl 4):99–105.
   PubMed Web of Science ®Google Scholar
• Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther. 1996;7:2101–2112.
   PubMed Web of Science ®Google Scholar
• Pittman DD, Alderman EM, Tomkinson KN, et al. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood. 1993;81:2925–2935.
   PubMed Web of Science ®Google Scholar
• Chao H, Liu Y, Rabinowitz J, et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther. 2000;2:619–623.
   PubMed Web of Science ®Google Scholar
• Sarkar R, Tetreault R, Gao G, et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood. 2004;103:1253–1260.
   PubMed Web of Science ®Google Scholar
• Scallan CD, Liu T, Parker AE, et al. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood. 2003;102:3919–3926.
   PubMed Web of Science ®Google Scholar
• Dong B, Nakai H, Xiao W. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther. 2010;18:87–92.
   PubMed Web of Science ®Google Scholar
• McIntosh J, Lenting PJ, Rosales C, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. 2013;121:3335–3344.
   PubMed Web of Science ®Google Scholar
• Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA. 1990;87:2211–2215.
   PubMed Web of Science ®Google Scholar
• Huser D, Gogol-Doring A, Lutter T, et al. Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome. PLoS Pathog. 2010;6:e1000985.
   Google Scholar
• Drew HR, Lockett LJ, Both GW. Increased complexity of wild-type adeno-associated virus-chromosomal junctions as determined by analysis of unselected cellular genomes. J Gen Virol. 2007;88:1722–1732.
   PubMed Web of Science ®Google Scholar
• Zhang C, Cortez NG, Berns KI. Characterization of a bipartite recombinant adeno-associated viral vector for site-specific integration. Hum Gene Ther. 2007;18:787–797.
   PubMed Web of Science ®Google Scholar
• Henckaerts E, Dutheil N, Zeltner N, et al. Site-specific integration of adeno-associated virus involves partial duplication of the target locus. Proc Natl Acad Sci USA. 2009;106:7571–7576.
   PubMed Web of Science ®Google Scholar
• Russell DW, Hirata RK. Human gene targeting by viral vectors. Nat Genet. 1998;18:325–330.
   PubMed Web of Science ®Google Scholar
• Khan IF, Hirata RK, Russell DW. AAV-mediated gene targeting methods for human cells. Nat Protoc. 2011;6:482–501.
   PubMed Web of Science ®Google Scholar
• Platt RJ, Chen S, Zhou Y, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014;159:440–455.
   PubMed Web of Science ®Google Scholar
• Chao H, Mansfield SG, Bartel RC, et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med. 2003;9:1015–1019.
   PubMed Web of Science ®Google Scholar
• Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397–405.
   PubMed Web of Science ®Google Scholar
• Schmidt F, Grimm D. CRISPR genome engineering and viral gene delivery: a case of mutual attraction. Biotechnol J. 2015;10:258–272.
   PubMed Web of Science ®Google Scholar
• Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520:186–191.
   PubMed Web of Science ®Google Scholar
• Tsai SQ, Zheng Z. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33:187–97.
   PubMed Web of Science ®Google Scholar
• Frock RL, Hu J, Meyers RM, et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol. 2015;33:179–186.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Y, Wu X, et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol. 2015;33:179–186.
   PubMed Web of Science ®Google Scholar
• Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016;351:84–88.
   PubMed Web of Science ®Google Scholar
• Barzel A, Paulk NK, Shi Y, et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature. 2015;517:360–364.
   PubMed Web of Science ®Google Scholar
• Sebastiano V, Zhen HH, Haddad B, et al. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Sci Transl Med. 2014;6:264ra163.
   PubMed Web of Science ®Google Scholar
• Rutledge EA, Russell DW. Adeno-associated virus vector integration junctions. J Virol. 1997;71:8429–8436.
   PubMed Web of Science ®Google Scholar
• Yang CC, Xiao X, Zhu X, et al. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J Virol. 1997;71:9231–9247.
   PubMed Web of Science ®Google Scholar
• Miller DG, Rutledge EA, Russell DW. Chromosomal effects of adeno-associated virus vector integration. Nat Genet. 2002;30:147–148.
   PubMed Web of Science ®Google Scholar
• Nakai H, Montini E, Fuess S, et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet. 2003;34:297–302.
   PubMed Web of Science ®Google Scholar
• Paulk NK, Wursthorn K, Wang Z, et al. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology. 2010;51:1200–1208.
   PubMed Web of Science ®Google Scholar
• Miller DG, Wang PR, Petek LM, et al. Gene targeting in vivo by adeno-associated virus vectors. Nat Biotechnol. 2006;24:1022–1026.
   PubMed Web of Science ®Google Scholar
• Persons DA, Baum C. Solving the problem of γ-retroviral vectors containing long terminal repeats. Mol Ther. 2011;19:229–231.
   PubMed Web of Science ®Google Scholar
• Li H, Malani N, Hamilton SR, et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood. 2011;117:3311–3319.
   PubMed Web of Science ®Google Scholar
• Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 2001;8:1343–1346.
   PubMed Web of Science ®Google Scholar
• Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007;317:477.
   PubMed Web of Science ®Google Scholar
• Wang P-R, Xu M, Toffanin S, et al. Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci USA. 2012;109:11264–11269.
   PubMed Web of Science ®Google Scholar
• Reiss J, Hahnewald R. Molybdenum cofactor deficiency: mutations in GPHN, MOCS1, and MOCS2. Hum Mutat. 2011;32:10–18.
   PubMed Web of Science ®Google Scholar
• Rosas LE, Grieves JL, Zaraspe K, et al. Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. Mol Ther. 2012;20:2098–2110.
   PubMed Web of Science ®Google Scholar
• Chandler RJ, LaFave MC, Varshney GK, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. 2015;125:870–880.
   PubMed Web of Science ®Google Scholar
• Zhong L, Malani N, Li M, et al. Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. Hum Gene Ther. 2013;24:520–525.
   PubMed Web of Science ®Google Scholar
• Nault JC, Datta S, Imbeaud S, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genetics. 2015;47: 1187–93.
   PubMed Web of Science ®Google Scholar
• Baader E, Toloczko A, Fuchs U, et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res. 2005;65:7888–7895.
   PubMed Web of Science ®Google Scholar
• Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44:765–769.
   PubMed Web of Science ®Google Scholar
• Paterlini-Brechot P, Saigo K, Murakami Y, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene. 2003;22:3911–3916.
   PubMed Web of Science ®Google Scholar
• Wang J, Chenivesse X, Henglein B, et al. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature. 1990;343:555–557.
   PubMed Web of Science ®Google Scholar
• Büning H, Schmidt M. Adeno-associated vector toxicity-to be or not to be? Mol Ther. 2015;23:1673–1675.
   PubMed Web of Science ®Google Scholar
• Berns KI, Byrne BJ, Flotte TR, et al. Adeno-associated virus type 2 and hepatocellular carcinoma? Hum Gene Ther. 2015;26:779–781.
   PubMed Web of Science ®Google Scholar
• Senapathy P, Carter BJ. Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells. J Biol Chem. 1984;259:4661–4666.
   PubMed Web of Science ®Google Scholar
• Russell DW, Grompe M. Adeno-associated virus finds its disease. Nat Genet. 2015;47:1104–1105.
   PubMed Web of Science ®Google Scholar
• Baudard M, Flotte TR, Aran JM, et al. Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. Hum Gene Ther. 1996;7:1309–1322.
   PubMed Web of Science ®Google Scholar
• Haberman RP, McCown TJ, Samulski RJ. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol. 2000;74:8732–8739.
   PubMed Web of Science ®Google Scholar
• Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199:381–390.
   PubMed Web of Science ®Google Scholar
• Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature. 2001;412:914–917.
   PubMed Web of Science ®Google Scholar
• Hermonat PL. Adeno-associated virus inhibits human papillomavirus type 16: a viral interaction implicated in cervical cancer. Cancer Res. 1994;54:2278–2281.
   PubMed Web of Science ®Google Scholar
• Mayor HD, Drake S, Stahmann J, et al. Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults. Am J Obstet Gynecol. 1976;126:100–104.
   PubMed Web of Science ®Google Scholar